Safety and Efficacy of a New Ultrathin Sirolimus-Eluting Stent with Abluminal Biodegradable Polymer in Real-World Practice
- Author:
Young Jin YOUN
1
;
Sang Yong YOO
;
Jun Won LEE
;
Sung Gyun AHN
;
Seung Hwan LEE
;
Junghan YOON
;
Jae Hyoung PARK
;
Woong Gil CHOI
;
Sungsoo CHO
;
Sang Wook LIM
;
Yang Soo JANG
;
Ki Hwan KWON
;
Nam Ho LEE
;
Joon Hyung DOH
;
Woong Chol KANG
;
Dong Woon JEON
;
Bong Ki LEE
;
Jung Ho HEO
;
Bum Kee HONG
;
Hyun Hee CHOI
Author Information
- Publication Type:Original Article
- From:Korean Circulation Journal 2020;50(4):317-327
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND OBJECTIVES:Recently, Genoss drug-eluting stent (DES)â„¢ stent comprising cobalt-chromium platform with an ultrathin strut thickness, sirolimus, and an abluminal biodegradable polymer was developed. Owing to the lack of substantial evidence for the safety and efficacy of this stent, we report 12-month results of the Genoss DESâ„¢ stent.
METHODS:We analyzed subjects who were eligible for a 12-month follow-up from the ongoing Genoss DESâ„¢ registry, which is a prospective, single-arm, observational, multicenter trial to investigate the clinical outcomes after the successful Genoss DESâ„¢ stent implantation among all-comers. The primary endpoint was a device-oriented composite outcome, defined as cardiac death, target vessel-related myocardial infarction, and target lesion revascularization at 12-month follow-up.
RESULTS:Among 622 subjects, the mean age of subjects was 66.5±10.4 years, 70.6% were males, 67.5% had hypertension, and 38.3% had diabetes. The implanted stent number, diameter, and length per patient were 1.5±0.8, 3.1±0.4 mm, and 36.0±23.3 mm, respectively. At 12-month clinical follow-up, the primary endpoint occurred only in 4 (0.6%) subjects.
CONCLUSIONS:The novel Genoss DESâ„¢ stent exhibited excellent safety and efficacy in real-world practice.
